These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 8869107)

  • 1. Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferon gamma (IFN gamma) are recognised by T cells while resisting destruction by natural killer (NK) cells.
    Zier KS; Gansbacher B
    Eur J Cancer; 1996 Jul; 32A(8):1408-12. PubMed ID: 8869107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcoma cells engineered to secrete IFN-gamma or IL-2 acquire sensitization to immune cell killing via different mechanisms.
    Flemming CL; Patel PM; Box G; Eccles SA; Collins MK
    Cytokine; 1997 May; 9(5):328-32. PubMed ID: 9195131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
    Kim TS; Xu WS; Sun T; Cohen EP
    Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.
    Pulaski BA; Clements VK; Pipeling MR; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2000 Apr; 49(1):34-45. PubMed ID: 10782864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
    Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
    Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of interferon-gamma treatment of rat tumour cells on their susceptibility to natural killer cell, macrophage and cytotoxic T-cell killing.
    Yeoman H; Robins RA
    Immunology; 1988 Feb; 63(2):291-7. PubMed ID: 2965096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection.
    Hara I; Nguyen H; Takechi Y; Gansbacher B; Chapman PB; Houghton AN
    Int J Cancer; 1995 Apr; 61(2):253-60. PubMed ID: 7705956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.
    Bannerji R; Arroyo CD; Cordon-Cardo C; Gilboa E
    J Immunol; 1994 Mar; 152(5):2324-32. PubMed ID: 7907636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IFN-gamma production and cytotoxicity of IL-2-activated murine NK cells are differentially regulated by MHC class I molecules.
    Kubota A; Lian RH; Lohwasser S; Salcedo M; Takei F
    J Immunol; 1999 Dec; 163(12):6488-93. PubMed ID: 10586040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs.
    Rosenthal FM; Cronin K; Bannerji R; Golde DW; Gansbacher B
    Blood; 1994 Mar; 83(5):1289-98. PubMed ID: 8118032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
    Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
    Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.
    Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S
    J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
    Frey AB; Cestari S
    Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine.
    Comes A; Rosso O; Orengo AM; Di Carlo E; Sorrentino C; Meazza R; Piazza T; Valzasina B; Nanni P; Colombo MP; Ferrini S
    J Immunol; 2006 Feb; 176(3):1750-8. PubMed ID: 16424205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer activity in cloned cytotoxic T lymphocytes: regulation by interleukin 2, interferon, and specific antigen.
    Brooks CG; Holscher M; Urdal D
    J Immunol; 1985 Aug; 135(2):1145-52. PubMed ID: 2409140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of IFN-gamma and interleukin-1beta on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic T lymphocytes.
    Schiltz PM; Gomez GG; Read SB; Kulprathipanja NV; Kruse CA
    J Interferon Cytokine Res; 2002 Dec; 22(12):1209-16. PubMed ID: 12581494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine dependent inverse regulation of CD54 (ICAM1) and major histocompatibility complex class I antigens by nuclear factor kappaB in HEp2 tumor cell line: effect on the function of natural killer cells.
    Jewett A; Wang MY; Teruel A; Poupak Z; Bostanian Z; Park NH
    Hum Immunol; 2003 May; 64(5):505-20. PubMed ID: 12691701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.